Impact of Spinal Surgery on Intrathecal Nusinersen Injections in Pediatric Spinal Muscular Atrophy

被引:0
|
作者
Aksoy, Taha [1 ]
Ramazanov, Rafik [2 ]
Yildiz, Sibel Oz [3 ]
Demirkiran, Gokhan [1 ]
Haliloglu, Goknur [3 ]
Yazici, Muharrem [2 ]
机构
[1] Hacettepe Univ, Fac Med, Dept Orthoped & Traumatol, Ankara, Turkiye
[2] Pediat Orthoped Spine Ctr, Cinnah Caddesi 112-2, TR-06690 Ankara, Turkiye
[3] Hacettepe Univ, Fac Med, Dept Pediat, Div Pediat Neurol, Ankara, Turkiye
关键词
spinal muscular atrophy; scoliosis; deformity; spinal surgery; nusinersen; intrathecal administration; injection; SHAM CONTROL;
D O I
10.1097/BPO.0000000000002703
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background:Complex spinal deformities necessitate surgical interventions that may intervene with intrathecal injections in patients with spinal muscular atrophy (SMA). This study aimed to determine the effect of spinal deformity correction surgery on nusinersen administration.Methods:Pediatric patients with SMA, operated by a single surgeon, either via magnetically controlled growing rod (MCGR) or definitive fusion (DF) with skip instrumentation, were evaluated retrospectively in terms of safety and feasibility of intrathecal injections. Patients' and their parents' perspectives were evaluated through a questionnaire regarding any shift in the setting of injections.Results:Fourteen patients with 15 spinal surgeries (10 MCGR and 5 DF) were included. Eleven patients received intrathecal treatment both before and after the surgery. Preoperative (n=3) and postoperative (n=9) fluoroscopic guidance was required leading to a shift in the application settings in 6 patients. Of 106 preoperative injections, 15% required fluoroscopy and 2% required anesthesia. Postoperatively, of 88 injections, 73% required fluoroscopy and 26% required anesthesia. No patients discontinued intrathecal injections due to technical difficulties associated with the spinal surgery.Conclusions:This study demonstrates that spinal surgery does not prevent safe and successful intrathecal nusinersen injections. In the DF group, the skip instrumentation technique provided access to interlaminal space for intrathecal injections. In either surgical group, no further auxillary approach was required. Modifications in the injection technique require an institutional approach, and concerns of patients and their families should be addressed accordingly.Level of Evidence:IV
引用
收藏
页码:e641 / e646
页数:6
相关论文
共 50 条
  • [21] Nusinersen (Spinraza) for Spinal Muscular Atrophy
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1517): : 50 - 52
  • [22] Nusinersen for adults with spinal muscular atrophy
    Arslan, Doruk
    Inan, Berin
    Kilinc, Muhammed
    Bekircan-Kurt, Can Ebru
    Erdem-Ozdamar, Sevim
    Tan, Ersin
    NEUROLOGICAL SCIENCES, 2023, 44 (07) : 2393 - 2400
  • [23] Nusinersen for adults with spinal muscular atrophy
    Doruk Arslan
    Berin Inan
    Muhammed Kilinc
    Can Ebru Bekircan-Kurt
    Sevim Erdem-Ozdamar
    Ersin Tan
    Neurological Sciences, 2023, 44 : 2393 - 2400
  • [24] Transforaminal intrathecal delivery of nusinersen for older children and adults with spinal muscular atrophy and complex spinal anatomy: an analysis of 200 consecutive injections
    Weaver, John J.
    Hallam, Danial K.
    Chick, Jeffrey Forris Beecham
    Vaidya, Sandeep
    Shin, David S.
    Natarajan, Niranjana
    Rad, Nassim
    Reis, Joseph
    Koo, Kevin S. H.
    Shivaram, Giridhar M.
    Thibodeau, Ashley
    Apkon, Susan
    Monroe, Eric James
    JOURNAL OF NEUROINTERVENTIONAL SURGERY, 2021, 13 (01) : 75 - +
  • [25] Nusinersen for the treatment of spinal muscular atrophy
    Chiriboga, Claudia A.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2017, 17 (10) : 955 - 962
  • [26] Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
    Stolte, Benjamin
    Totzeck, Andreas
    Kizina, Kathrin
    Bolz, Saskia
    Pietruck, Lena
    Moenninghoff, Christoph
    Guberina, Nika
    Oldenburg, Denise
    Forsting, Michael
    Kleinschnitz, Christoph
    Hagenacker, Tim
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
  • [27] Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy
    Orbach, Rotem
    Sagi, Liora
    Sadot, Efraim
    Latzer, Itay Tokatly
    Shtamler, Anna
    Zisberg, Tehila
    Fattal-Valevski, Aviva
    MUSCLE & NERVE, 2022, 66 (06) : 762 - 766
  • [28] Budget Impact Analysis of Nusinersen for Spinal Muscular Atrophy in China
    Duan, Chengaxin
    Ai, Dandan
    Xu, Qian
    Sui, Binyan
    Zhao, Kun
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 34 : 9 - 13
  • [29] Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
    Pera, Maria Carmela
    Coratti, Giorgia
    Bovis, Francesca
    Pane, Marika
    Pasternak, Amy
    Montes, Jacqueline
    Sansone, Valeria A.
    Dunaway Young, Sally
    Duong, Tina
    Messina, Sonia
    Mizzoni, Irene
    D'Amico, Adele
    Civitello, Matthew
    Glanzman, Allan M.
    Bruno, Claudio
    Salmin, Francesca
    Morando, Simone
    De Sanctis, Roberto
    Sframeli, Maria
    Antonaci, Laura
    Frongia, Anna Lia
    Rohwer, Annemarie
    Scoto, Mariacristina
    De Vivo, Darryl C.
    Darras, Basil T.
    Day, John
    Martens, William
    Patanella, Katia A.
    Bertini, Enrico
    Muntoni, Francesco
    Finkel, Richard
    Mercuri, Eugenio
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2021, 8 (08): : 1622 - 1634
  • [30] Stabilization of Respiratory Function in Pediatric Spinal Muscular Atrophy Treated with Nusinersen
    Chacko, A.
    Deegan, S.
    Sly, P. D.
    Gauld, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201